As the biopharma industry grows ever more competitive, with multiple companies developing therapies for the same indications, being first to market carries a significant advantage.
However, few drug developers have the internal resources to streamline process development, scaling and manufacturing, all while maintaining regulatory excellence. And developers increasingly look outside their organizations for the support they need to bring novel therapies to market.
Against this backdrop, contract development and manufacturing organizations (CDMOs) play a key role in successful launches – and finding the right partner is essential to hit key development milestones, including successful process performance qualification (PPQ).
Here, we’ll discuss how Rentschler Biopharma helped its client beat rival companies to become first to market, condensing GMP1 to PPQ development into an “impossible” 12 months.
In this playbook you’ll learn how Rentschler Biopharma …
Download the Playbook here: